Skip to main content

What the FDA labels say about taking them together

Nefazodone and palbociclib

Palbociclib's FDA label of July 2, 2026 names nefazodone in its drug interactions section; the nefazodone label PlainMeds reads does not name palbociclib. The palbociclib label: “Avoid concomitant use of strong CYP3A inhibitors.”

Check it at the source: the nefazodone FDA label on DailyMed (effective July 31, 2025, Teva Pharmaceuticals USA, Inc.); the palbociclib FDA label on DailyMed (effective July 2, 2026, Pfizer Laboratories Div Pfizer Inc).

What does the nefazodone label say about palbociclib?

Nefazodone's label (effective July 31, 2025) does not name palbociclib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Nefazodone Hydrochloride), Teva Pharmaceuticals USA, Inc., effective July 31, 2025 (SPL set 51ff7db5-aaf9-4c3c-86e6-958ebf16b60f), via openFDA; the full label on DailyMed

What does the palbociclib label say about nefazodone?

Palbociclib label, drug interactions

Avoid concomitant use of strong CYP3A inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, and voriconazole).

Source: FDA drug label (Ibrance), Pfizer Laboratories Div Pfizer Inc, effective July 2, 2026 (SPL set fecbdd7d-b729-41b5-9872-231b8fe104ce), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

2Nefazodone generic labelers
0Palbociclib generic labelers
NefazodonePalbociclib
Labeled forDepressionBreast cancer
Boxed warningYesNo
Pharmacy cost (NADAC)$1.17 per tablet 100 mg tabletn/a
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?